Risk of Acute Thromboembolic Events With Oral Contraceptive Use
Authors:
- Rachel Peragallo UrrutiaRURachel Peragallo Urrutia
- Remy R. CoeytauxRCRemy R. Coeytaux
- Amanda J. McBroomAMAmanda J. McBroom
- Jennifer M. GierischJGJennifer M. Gierisch
- Laura J. HavrileskyLHLaura J. Havrilesky
- Patricia G. MoormanPMPatricia G. Moorman
- William J. LoweryWLWilliam J. Lowery
- Michaela DinanMDMichaela Dinan
- Vic HasselbladVHVic Hasselblad
- Gillian D. SandersGSGillian D. Sanders
- Evan R. MyersEMEvan R. Myers
- 1 August 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 122 (2) , 380-389
Abstract
To estimate the risk of venous thromboembolism, stroke, or myocardial infarction (MI) associated with the use of oral contraceptive pills (OCPs) and to describe how these risks vary by dose or formulation. We searched PubMed, Embase, the Cochrane Database of Systematic Reviews, and ClinicalTrials.gov for studies published from January 1995 through June 2012 that evaluated the association between OCP use and risk of venous thromboembolism, stroke, or MI. We reviewed 6,476 citations. We included English-language, controlled studies with human participants reporting a quantitative association between exposure to OCPs and outcomes of venous thromboembolism, stroke, or MI. Two investigators independently reviewed articles for inclusion or exclusion; discordant decisions were resolved by team review and consensus. Random-effects meta-analysis was used to generate summary odds ratios (ORs). Fifty studies met inclusion criteria. There were no randomized clinical trials. We found threefold increased odds of venous thromboembolism among current compared with noncurrent OCP users (14 studies; OR 2.97, 95% confidence interval [CI] 2.46–3.59). We found twofold increased odds of ischemic stroke (seven studies; OR 1.90, 95% CI 1.24–2.91). There was no evidence of increased risk of hemorrhagic stroke (four studies; OR 1.03, 95% CI 0.71–1.49) or MI (eight studies; OR 1.34, 95% CI 0.87–2.08). Current use of combined OCPs is associated with increased odds of venous thromboembolism and ischemic stroke but not hemorrhagic stroke or MI.Keywords
This publication has 15 references indexed in Scilit:
- Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9BMJ, 2011
- AHRQ Series Paper 5: Grading the strength of a body of evidence when comparing medical interventions—Agency for Healthcare Research and Quality and the Effective Health-Care ProgramJournal of Clinical Epidemiology, 2010
- Range of published estimates of venous thromboembolism incidence in young womenContraception, 2007
- Trends in the Incidence of Venous Thromboembolism during Pregnancy or Postpartum: A 30-Year Population-Based StudyAnnals of Internal Medicine, 2005
- The transnational study on oral contraceptives and the health of young women. Methods, results, new analyses and the healthy user effectHuman Reproduction Update, 1999
- Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptivesContraception, 1998
- Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control studyThe Lancet, 1997
- Incidence of Stroke and Myocardial Infarction in Women of Reproductive AgeStroke, 1997
- Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagenThe Lancet, 1995
- Investigation of relation between use of oral contraceptives and thromboembolic disease.BMJ, 1968